Pharmaceutical industry sees FDA approvals and major acquisitions

The pharmaceutical sector saw several significant developments, including the FDA approval of Ultragenyx’s Fayuvi (rebisufligene etisparvovec-hopf) as the first treatment for Sanfilippo syndrome type A.

In corporate movements, Lisata Therapeutics acquired Marea Therapeutics while simultaneously securing $225 million in concurrent financing. Additionally, mAbxience and Sandoz announced a partnership to develop and globally commercialize an emicizumab biosimilar for hemophilia A.

Regarding drug policy, former U.S. Representative Joe Cunningham, acting as a spokesperson for the Pharmaceutical Reform Alliance, argued that codifying Most-Favored-Nation pricing into law is necessary to address drug costs, dismissing industry arguments regarding innovation.